MX2022015613A - Composiciones de benzofurano beneficiosas para trastornos mentales o mejoramiento mental. - Google Patents

Composiciones de benzofurano beneficiosas para trastornos mentales o mejoramiento mental.

Info

Publication number
MX2022015613A
MX2022015613A MX2022015613A MX2022015613A MX2022015613A MX 2022015613 A MX2022015613 A MX 2022015613A MX 2022015613 A MX2022015613 A MX 2022015613A MX 2022015613 A MX2022015613 A MX 2022015613A MX 2022015613 A MX2022015613 A MX 2022015613A
Authority
MX
Mexico
Prior art keywords
compositions
benzofuran
enhancement
advantageous
mental disorders
Prior art date
Application number
MX2022015613A
Other languages
English (en)
Inventor
Matthew Baggott
Original Assignee
Tactogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tactogen Inc filed Critical Tactogen Inc
Publication of MX2022015613A publication Critical patent/MX2022015613A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/80—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/58—Radicals substituted by nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Composiciones de benzofurano farmacéuticamente activas para el tratamiento de trastornos mentales o para el mejoramiento mental, que incluye para terapia entactogénica; la presente invención también incluye compuestos de benzofurano, composiciones y métodos para modular en general la actividad del sistema nervioso central y tratar trastornos del sistema nervioso central.
MX2022015613A 2020-06-08 2021-06-08 Composiciones de benzofurano beneficiosas para trastornos mentales o mejoramiento mental. MX2022015613A (es)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US202063036382P 2020-06-08 2020-06-08
US202063046496P 2020-06-30 2020-06-30
US202063048616P 2020-07-06 2020-07-06
US202063055897P 2020-07-23 2020-07-23
US202063062434P 2020-08-06 2020-08-06
US202163149223P 2021-02-13 2021-02-13
US202163165731P 2021-03-24 2021-03-24
PCT/US2021/036479 WO2021252538A2 (en) 2020-06-08 2021-06-08 Advantageous benzofuran compositions for mental disorders or enhancement

Publications (1)

Publication Number Publication Date
MX2022015613A true MX2022015613A (es) 2023-04-04

Family

ID=78845853

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022015613A MX2022015613A (es) 2020-06-08 2021-06-08 Composiciones de benzofurano beneficiosas para trastornos mentales o mejoramiento mental.

Country Status (10)

Country Link
US (2) US11767305B2 (es)
EP (1) EP4161503A4 (es)
JP (1) JP2023530092A (es)
KR (1) KR20230066313A (es)
CN (1) CN116075300A (es)
AU (1) AU2021289434A1 (es)
CA (1) CA3179785A1 (es)
IL (1) IL298769A (es)
MX (1) MX2022015613A (es)
WO (1) WO2021252538A2 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020157972A1 (en) * 2019-02-01 2020-08-06 Nec Corporation Estimation apparatus, method and program
WO2022251699A1 (en) * 2021-05-28 2022-12-01 Adamo Bioscience Inc. Compositions and methods for treatment of sexual dysfunction and related diseases, disorders, and conditions
WO2022256720A2 (en) 2021-06-03 2022-12-08 Arcadia Medicine, Inc. Enantiomeric entactogen compositions and methods of their use
US11993577B2 (en) 2021-09-01 2024-05-28 Empathbio, Inc. Synthesis of MDMA or its optically active (R)- or (S)-MDMA isomers
WO2023056102A1 (en) 2021-10-01 2023-04-06 ATAI Life Sciences AG Novel prodrugs of mdma, mda, and derivatives thereof
CA3239518A1 (en) * 2021-12-08 2023-06-15 Tactogen Inc Benzofuran salt morphic forms and mixtures for the treatment of mental disorders or mental enhancement
AU2022407174A1 (en) * 2021-12-09 2024-06-13 Tactogen Inc Specialized combinations for mental disorders or mental enhancement
WO2023129958A2 (en) 2021-12-28 2023-07-06 ATAI Life Sciences AG Nitric oxide releasing prodrugs of mda and mdma

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2164009A1 (en) 1993-06-14 1994-12-22 Robert L. Dow Secondary amines as antidiabetic and antiobesity agents
US20050032873A1 (en) * 2003-07-30 2005-02-10 Wyeth 3-Amino chroman and 2-amino tetralin derivatives
US7218867B2 (en) 2004-08-27 2007-05-15 Static Control Components, Inc. Systems and methods for imaging components
CN101218223A (zh) * 2005-04-22 2008-07-09 惠氏公司 苯并二烷和苯并二氧戊环衍生物及其应用
EP1871358A1 (en) 2005-04-22 2008-01-02 Wyeth Benzofuranyl alkanamine derivatives and uses thereof as 5-ht2c agonists
WO2007146890A2 (en) * 2006-06-09 2007-12-21 Auspex Pharmaceuticals, Inc. Preparation and utility of substituted pyrazole compounds with cannabinoid receptor activity
US20090048288A1 (en) * 2007-08-13 2009-02-19 H. Lundbeck A/S Method of treating stress-mediated depression
EP3705469A1 (en) 2014-12-09 2020-09-09 GOLAN, Ezekiel Binge behavior regulators
WO2021173273A1 (en) 2020-02-28 2021-09-02 Universitätsspital Basel Controlling effects after 5ht2a agonists administration
CN115811975A (zh) 2020-05-05 2023-03-17 巴塞尔大学医院 增强lsd、赛洛西宾或其他致幻剂的急性情绪效应特征的mdma治疗
WO2021257169A1 (en) 2020-06-15 2021-12-23 Universitätsspital Basel Mdma response prediction
CN116056705A (zh) 2020-08-05 2023-05-02 巴塞尔大学医院 用于dmt辅助心理疗法的静脉内dmt施用方法
WO2022106947A1 (en) 2020-11-18 2022-05-27 Liechti Matthias Emanuel Mdma prodrugs to assist psychotherapy
WO2022109050A1 (en) 2020-11-18 2022-05-27 Bexson Biomedical, Inc. Complexing agent salt formulations of pharmaceutical compounds
CA3203642A1 (en) 2020-12-02 2022-06-09 The Johns Hopkins University Restoration of motor function post-neurological injury using psychedelics

Also Published As

Publication number Publication date
CN116075300A (zh) 2023-05-05
KR20230066313A (ko) 2023-05-15
US20240083864A1 (en) 2024-03-14
US20230150963A1 (en) 2023-05-18
EP4161503A4 (en) 2024-07-03
WO2021252538A3 (en) 2022-01-20
US11767305B2 (en) 2023-09-26
EP4161503A2 (en) 2023-04-12
AU2021289434A1 (en) 2023-01-19
WO2021252538A2 (en) 2021-12-16
CA3179785A1 (en) 2021-12-16
JP2023530092A (ja) 2023-07-13
IL298769A (en) 2023-02-01

Similar Documents

Publication Publication Date Title
MX2022015613A (es) Composiciones de benzofurano beneficiosas para trastornos mentales o mejoramiento mental.
WO2020163823A3 (en) Therapeutic agents and methods of treatment
WO2020086726A3 (en) Nerve stimulation for treating migraine and other headache conditions
MX2022016427A (es) Inhibidores de glicolato oxidasa para el tratamiento de enfermedades.
CR20220626A (es) Compuestos para el tratamiento de enfermedades y trastornos asociados a braf
SG169224A1 (en) Method for treatment of tumors using nordihydrogualaretic acid derivatives
MX2023000056A (es) Compuestos tricíclicos de urea como inhibidores de la variante v617f de la cinasa de janus 2 (jak2 v617f).
MX2021011488A (es) Compuestos y usos de estos.
MX2021012391A (es) Composiciones y metodos para mejorar la salud de la piel y para el tratamiento y la prevencion de enfermedades, trastornos y afecciones asociados con microbios patogenos.
EA202192122A1 (ru) Соединения, обладающие активностью индуцирования ферроптоза, и способы их применения
MX2022006807A (es) Análogos de rapamicina y usos de estos.
MX2023009723A (es) Inhibidores de tyk2 y sus usos.
MX2023009682A (es) Inhibidores de tyk2 y sus usos.
MX2018010946A (es) Inhibidores de cxcr-2 para tratamiento de trastornos de artropatia por cristales.
EA201991650A1 (ru) Способы лечения неврологических расстройств
MX2022002597A (es) Métodos de tratamiento de la epilepsia usando los métodos.
MX2023004942A (es) Compuestos biciclicos y usos de los mismos para el tratamiento de enfermedades.
MX2023003677A (es) Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos.
MX2020009942A (es) Compuestos y usos de los mismos.
MX2022006176A (es) Terapia combinada que comprende un inhibidor de alk2 y un inhibidor de jak2.
MX2022009762A (es) Moduladores del purinorreceptor 3 p2x (p2x3).
MX2022014925A (es) Moduladores de il-17a.
MX2023003675A (es) Inhibidores de hidroxiesteroide 17beta-deshidrogenasa 13 (hsd17b13) y usos de estos.
MX2022011888A (es) Tratamiento de trastornos respiratorios.
MX2023005591A (es) Metodos de tratamiento de enfermedades y trastornos.